Acebrophylline is a unique, fixed-dose combination drug containing Acebrophylline (a xanthine derivative) and Ambroxol. It acts as a mucolytic, bronchodilator, and anti-inflammatory agent, primarily used in the management of chronic obstructive airway diseases. It improves lung function by reducing mucus viscosity, enhancing mucociliary clearance, and relaxing bronchial smooth muscles.
Adult: One capsule/tablet of Acebrophylline (100mg) + Ambroxol (75mg) twice daily, preferably after meals.
Note: Administer orally after food to minimize gastric irritation. Swallow the capsule/tablet whole with a full glass of water. Do not crush or chew sustained-release formulations. Maintain adequate hydration to aid mucus clearance.
Acebrophylline exerts a dual action: 1) Bronchodilation via non-selective inhibition of phosphodiesterase (PDE) enzymes (mainly PDE3 and PDE4), leading to increased intracellular cyclic AMP (cAMP). This relaxes bronchial smooth muscle. 2) Anti-inflammatory and mucoregulatory effects by inhibiting the release of inflammatory mediators (like TNF-α, IL-4, IL-5, IL-13) from mast cells, eosinophils, and macrophages. Ambroxol, the other component, is a potent mucolytic that breaks down acid mucopolysaccharide fibers in sputum, stimulates surfactant production, and enhances mucociliary clearance.
Pregnancy: Category C: Animal studies have shown adverse effects on the fetus. There are no adequate and well-controlled studies in pregnant women. Use only if the potential benefit justifies the potential risk to the fetus, especially in the first trimester.
Driving: May cause dizziness, lightheadedness, or blurred vision. Patients should be cautioned about operating machinery or driving until they are sure they are not affected.
| Ciprofloxacin/Levofloxacin (Fluoroquinolones) | Inhibits Acebrophylline metabolism, leading to increased serum levels and toxicity risk. | Major |
| Erythromycin, Clarithromycin | Inhibit CYP1A2/3A4, increasing Acebrophylline levels. | Major |
| Phenytoin, Phenobarbital, Carbamazepine | Induce hepatic enzymes, decreasing Acebrophylline levels and efficacy. | Moderate |
| Cimetidine | Inhibits metabolism, increases Acebrophylline levels. | Moderate |
| Warfarin | Acebrophylline may potentiate anticoagulant effect; monitor INR closely. | Moderate |
| Beta-2 Agonists (Salbutamol, Formoterol) | Additive risk of hypokalemia and tachycardia. | Moderate |
| Theophylline | Additive xanthine toxicity; concurrent use is contraindicated. | Major |
| Alcohol | May increase CNS depressant effects and gastric irritation. | Minor |
Same composition (Acebrophylline (100mg)), different brands: